by TractManager | Jul 27, 2018 | Emerging Technology Report
Xhance (formerly OPN-375) is a drug-device product for the treatment of nasal polyposis in adults. The product combines a novel, closed palate, bidirectional drug delivery platform with fluticasone propionate, which is a topical steroid. The drug delivery device is...
by TractManager | Jul 26, 2018 | Emerging Technology Report
Tibsovo is a first-in-class oral targeted small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (IDH1) designed to decrease accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG), resulting in reduced blast counts and increased percentages of...
by TractManager | Jul 24, 2018 | Health Technology Assessment
Health Problem: Osteoarthritis (OA) of the knee is a common, debilitating, painful condition with few treatment options. The cartilage between the bones degenerates, no longer providing a smooth, gliding surface for motion or adequate cushioning. Damaged articular...
by TractManager | Jul 23, 2018 | Health Technology Assessment
Health Problem: Myelomeningocele (MMC) is the most severe form of spina bifida, in which the neural tube does not completely close and a sac of fluid, including cerebrospinal fluid, meninges, and possibly damaged parts of the spinal cord and nerves, protrudes through...
by TractManager | Jul 20, 2018 | Emerging Technology Report
RBX2660 is a microbiota-based investigational product for fecal microbiota transplantation proposed to treat recurrent Clostridium difficile infection. It is derived from fresh stool from multiple donors; both donors and stool samples are methodically screened. Pooled...
Recent Comments